# Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

> **NCT01439750** · PHASE1 · UNKNOWN · sponsor: **Milton S. Hershey Medical Center** · enrollment: 13 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** bortezomib
- **DRUG:** Cladribine

## Key facts

- **NCT ID:** NCT01439750
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2018-08
- **Final completion:** 2020-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439750, "Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01439750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*